Partner Judith Waltz was quoted in a Compliance Cosmos article, “In Ruling That Will Shake Up How CMS Issues Guidance, Supreme Court Rejects DSH Formula,” about a U.S. Supreme Court decision throwing out a Medicare formula for calculating disproportionate share hospital (DSH) payments because it never went through formal rulemaking.
Going forward, Waltz said, there still are a lot of open issues that will need to be hashed out in the courts. “CMS will take an action and someone will go into court and say, ‘that’s an invalid action because the underlying requirement was not noticed and commented, so we can’t be held to that standard because it’s just CMS’s opinion,’” she said.
It’s also unclear what the decision means for routine guidance, Waltz said. “CMS can take the risk and say its guidance is only interpretive, but I think it will be another area of challenge,” she said.
(Subscription required.)
Going forward, Waltz said, there still are a lot of open issues that will need to be hashed out in the courts. “CMS will take an action and someone will go into court and say, ‘that’s an invalid action because the underlying requirement was not noticed and commented, so we can’t be held to that standard because it’s just CMS’s opinion,’” she said.
It’s also unclear what the decision means for routine guidance, Waltz said. “CMS can take the risk and say its guidance is only interpretive, but I think it will be another area of challenge,” she said.
(Subscription required.)
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."